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1 Abstract 
1.1 Aim of the Study 
Living tissue engineered vascular grafts are a next generation treatment for arterial 
replacements with enormous potential. However, despite promising preclinical trials, there is 
currently no information available on how biological age of the implanted graft compares to 
the corresponding native artery. Major remodelling processes and maturation of tissue 
engineered arteries have been observed in vivo, especially in regard to cell number and 
extracellular matrix, but only little is known about the origin of these cells, the driving forces 
behind the remodelling process and their impact on graft functionality and survival. However, 
clarification of the mechanisms of tissue/cellular remodelling processes is critical for future 
clinical implementation of cardiovascular grafts. 
Analyzing a 240 weeks follow-up sheep study with implanted tissue engineered pulmonary 
arteries provided the opportunity to compare the cellular age of tissue engineered 
cardiovascular constructs and their native counterparts focusing on telomere length as a 
renowned endogenous marker linked to cellular and organismal aging.  
1.2 Methods and Results 
Relative telomere length and telomerase activity were determined of serially passaged 
vascular myofibroblasts harvested from the external jugular and saphenous veins of three 
Swiss Alpine Lambs. Quantitative telomere length analysis (Q-FISH) and immunohistological 
analyses were conducted in explanted pulmonary artery grafts fabricated from biodegradable 
scaffold material seeded with autologous vascular cells 5, 20, 50, 100 and 240 weeks post 
implantation.  
The results show strong evidence that the cell age of tissue engineered pulmonary arteries is 
significantly lower than in their native counterparts. Furthermore, histological analyses 
provide important cues on the basic remodelling processes of a tissue-engineered graft.  
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1.3 Conclusion 
This study provides evidence that telomere length may be used to assess cellular age in 
tissue engineered vascular grafts. Remodeling processes are crucial to ensure growth and 
graft functionality in a growing sheep model and may be, in combination with the in vitro graft 
production conditions, at the cost of premature aging. 
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2 Introduction 
2.1 Rationale of Tissue Engineering 
The concept of tissue engineering is an integrative part of regenerative cardiovascular 
medicine and offers an alternative approach to current treatment strategies in a variety of 
cardiovascular disorders such as congenital or acquired complex heart diseases or 
peripheral arterial disease [1,2]. With stem cell based therapies continuously gaining 
attention, the concept has also been introduced to the treatment of myocardial infarction and 
severe heart failure [3,4]. One of the major motivations is substantiated by the replacement 
of compromised biological structures for which the use of today’s “conventional” non-
biodegradable grafts is limited for example due to their inability to adapt to growth and 
development of the target structure. Tissue engineering aims to replace dysfunctional tissues 
by using an in vitro generated fully functional living construct containing cells, ideally of 
autologous origin, in combination with biodegradable scaffold materials [5]. Key 
characteristics of these constructs are their potential to undergo self-renewal, healing and 
remodeling processes post implantation [1,6]. However, several aspects such as the 
individual contribution of these processes to long-term integration and aging of a tissue-
engineered vascular graft (TEVG) are poorly understood and need to be addressed in order 
to further improve graft quality and fabrication processes and to facilitate the design of 
biologically dynamic scaffold materials. 
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 Figure 1:  Design of a tissue engineered vascular graft (TEVG).  
 [A] Tissue or cells are harvested from the host/donor animal, isolated and 
prepared for cultivation. [B] After the expansion phase to obtain sufficient 
cell numbers, the cells are seeded onto biodegradable scaffolds [C] 
Tissue maturation and conditioning is achieved using a pulsatile 
flow/pressure system [D] mimicking an in vivo environment before 
implanting the TEVG into the host animal.  
2.2 Graft remodeling – What happens to the cells? 
Several studies addressing remodeling processes in tissue engineered cardiovascular grafts 
have been published. Stock et al. [7] used poly-4-hydroxybutyric acid patches seeded with 
autologous cells transgenic for green fluorescence protein (GFP) for pulmonary artery 
augmentation in a lamb model. The results demonstrated an increased DNA content of the 
seeded patches until day 49 of the implantation period, suggesting an increase of the total 
cell number within the graft. In addition, ingrowth of native cells into an unseeded control 
patch from its surroundings after an implantation period of 140 days has been observed. 
Data presented by Matsumura et al. [8] imply that canine bone marrow cells (BMC) initially 
seeded onto a co-polymeric scaffold and circulating endothelial cells contribute to 
histogenesis of a vascular autograft. BMCs were labeled with carboxyfluorescein diacetate 
succinimidyl ester (CFDA-SE) before seeding and could be followed up until eight weeks 
post implantation. Further investigation of transplanted pulmonary artery patches by Mettler 
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et al. [9] consisted of green and red fluorescent protein (GFP and RFP, respectively) 
retrovirally labeled endothelial progenitor and mesenchymal stem cells as a cell source. He 
reported a cellular persistence of 66% after 6 weeks by measuring immunofluorescent 
signals of seeded GFP and RFP transduced cells.  
There is only limited information available regarding results on long-term remodeling 
processes. However, understanding of these processes is mandatory for any future clinical 
application to ensure graft durability, ideally over a patient’s lifetime. In accordance to the 
results of Stock et al., Hoerstrup and coworkers demonstrated an approximately fivefold 
increase in the DNA content, comparing a pulmonary vascular graft prior to implantation and 
at 100 weeks post implantation, reaching similar DNA amounts compared to native 
pulmonary artery [6]. Three mechanisms are proposed to contribute to the remodeling 
processes: (i) proliferation and differentiation of the cells used to produce the graft [8,10], (ii) 
cell migration from adjacent tissue [9-12] and (iii) recruitment of circulating progenitor cells [9, 
12]. 
2.3 Technologies to monitor cell remodeling processes 
Various labeling techniques have been developed to monitor and identify remodeling 
processes on a cellular level. These include genetic markers such as sex-mismatched donor-
host systems, fluorescent organic dyes, nanoparticles such as carbon nanotubes, 
magnetodendrimers and quantum dots and transgenic labeling such as viral transduction or 
transfection with reporter genes (LacZ, GFP, norepinephrine transporter, sodium-iodide 
symporter). Due to their individual properties and labeling mechanisms, they provide an 
enormous tool box for tissue engineering purposes and can be tailored to particular needs. 
2.3.1 Cell labeling 
Many cell labeling techniques available today present a valuable tool to assess cellular fate. 
The fact that they are all artificially introduced or added to viable cells which in some cases 
adversely affects cell functionality is one of their common undesirable features [13]. 
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Moreover, cell labeling requires a substantial amount of time or extensive preparation of cell 
populations before they are accessible to analyses, especially if large numbers of cells are 
required to produce the tissue engineered construct. We therefore sought for an endogenous 
marker which could complement available techniques and provide information even in long 
term studies of more than 20 weeks which has thus far been a mutual shortcoming of most 
cell labeling methods. Telomere length may serve as such an endogenous marker due to the 
fact that in many settings, cells intended for seeding of tissue engineered grafts undergo a 
considerable number of population doublings before a sufficient amount of cells is reached. 
2.3.1.1 Fluorescent dyes 
Fluorescent dyes may be divided into several categories depending on their mechanism of 
staining [14]. (i) DNA-binding fluorescent dyes such as HOECHST 33342 and thiazole 
orange can be used for cell tracking in vivo up to several days but are inhibiting cell 
functions. (ii) Cytoplasmatic fluorescent dyes contain esterase sensitive sidechains which 
allows trapping of these molecules after membrane permeation. Calcein is well-known 
representative of this group and has been used for short duration in vivo lymphocyte 
migration studies [15]. (iii) Covalent coupling fluorescent dyes are characterized by high 
membrane permeability and subsequent coupling with intracellular molecules. In the case of 
CFDA-SE, cell labeling could be observed for up to 8 weeks [16]. 
2.3.1.2 Retroviral transduced reporter genes 
Transgenic technologies are meanwhile laboratory routine to label cells with fluorescence 
proteins such as enhanced yellow fluorescent protein (EYFP), GFP or RFP. However, these 
technologies are rather suited for small animal trials with low amount of cells required. 
Moreover, disappearance of the fluorescent signal can be either due to cell death, wash out 
during proliferation or gene silencing [17]. 
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2.4 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) offers a potent and particularly non-invasive tool to 
monitor processes in vivo. To generate sufficient MR contrast, cells can be labeled with 
supraparamagnetic iron oxides encapsulated in repeatedly branched molecules called 
carboxylated polyamidoamine dendrimers [18]. These magnetodendrimers allow non-specific 
and non-receptor mediated uptake and accumulation in cells and have been used to monitor 
muscle stem cell transfer in mice over a 14-day period [19]. In T2 and T1 weighed images, 
results show well-defined areas of decreased signal intensity corresponding to the correct 
location of the transferred stem cells in comparison with conventional histological analysis. 
Viability, proliferation and differentiation of labeled cells were reported to be similar to non-
labeled cells.  
However, reported by Terrovitis et al. [20] this method is indeed useful for localizing the 
anatomic site of cardiac stem cell transfer but it is not reliable for monitoring long-term cell 
viability, as the acquired signals may also originate from dead cells and from macrophages 
which have taken up the ferrum oxide particles.  
2.4.1.1 Carbon nanotubes and quantum dots 
The platform technology of carbon nanotubes is continuously on the rise for tissue 
engineering purposes since the discovery by Iijima et al. [21].  Nanotubes consist of a 
cylindrical structure with diameters in nanometer dimension and are multifunctional in terms 
of their individual structural and electronic properties defined by length, diameter and chirality 
[22]. Optical labeling of fibroblasts and murine myoblast stem cells by ingested single-walled 
carbon nanotubes was demonstrated in experiments by Heller et al [23]. By functionalizing 
nanotubes with gadolinium (termed gadonanotubes), this technology could be made 
accessible for MRI imaging, which due to their high contrast ability, offers future possibilities 
for monitoring engineered tissues [22, 24]. 
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Quantum dots are semiconductor nanocrystals with highly photostable characteristics. They 
have been proposed as an alternative to the conventionally used fluorophores for cell 
labeling. Experiments by Jaiswal et al. [25] showed that HeLa cells could be stably labeled 
with quantum dots over a week. He reported no interference in growth or differentiation of the 
cells. Using quantum dot antibody bioconjugates, the possibility exists to specifically label the 
cell type of interest. Quantum dots have overcome some of the shortcomings of fluorescent 
dies, such as their limited absorption range, their broad emission spectra and their 
vulnerability to photobleaching effects. However, quantum dots still have a limited lifetime in 
aqueous solutions [23]. In addition, quantum dot cores consist of semiconductor metals 
(CdS, CdSe, CdTe, ZnS, PbS) which may have cytotoxic effects when exposed to cellular 
components [23,26]. 
2.4.1.2 Host-Donor Sex Mismatch 
A sex mismatched model offers a very reliable technique to monitor cellular remodeling 
processes. Location of the Y-chromosome can be determined by fluorescence in situ 
hybridization using a DNA-probe [27,28]. It is not subject to washout or loss of signal 
strength. However, it is by definition not suitable in an autologous setting. 
2.5 Cell Aging 
The aforementioned labeling technologies have been successfully used in small and large 
animal trials. Sex mismatch is the most reliable marker to evaluate cell graft persistence. 
However, these technologies are hardly applicable for autologous long term preclinical 
animal model systems since the ideal marker is not subject to any artificial or transient 
labeling technique, respectively, and does not require nanoparticles or transgenic 
technologies which may hamper native cell phenotype and may lead to false positive signals.  
Therefore, we have decided to analyze telomere lengths to investigate aging effects and its 
suitability as an endogenous marker in long term animal trials.  
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2.5.1 Telomeres and telomere length 
Any cell with a linear genome uses RNA primers to initiate DNA replication at the lagging 
DNA strand. Removal of the RNA primer at the end of the lagging strand leaves a single 
strand overhang of unreplicated DNA. Due to the fact that the DNA replication process is 
semi-conservative and unidirectional in its nature, the inability to replicate this last piece of 
DNA has been termed the end-replication problem since polymerases cannot initiate the 
formation of DNA on a template de novo.  Without protective measures, this would eventually 
lead to the loss of terminal sequences by enzymatic degradation and end-to-end fusions of 
chromosomes or activation of DNA repair mechanisms. In 1973, the end-replication problem 
served Olovnikov as an explanation for the limited cell doubling potential of normal somatic 
cells in his theory of marginotomy [29] and by the 1980s, the molecular structure of the 
telomeric region of chromosomes  has been identified [30,31].  
Telomeres are repeated DNA-Sequences (5'-TTAGGG-3')n capping the end of 
chromosomes. In association with several proteins, the telomere system forms a t-loop [32, 
33], which provides protection against chromosomal instability and DNA damage response 
(DDR) pathways. The length of the telomeric repeats, measured as lengths of terminal 
restriction fragments (TRF, HinfI/RsaI) ranges from 6-7kbp in dermal fibroblasts [34], 9-12kbp 
in endothelial cells of the internal thoracic artery (age-dependent) [35],  12-21kbp in ovine 
skin fibroblasts derived from 1-36 month old animals [36] to 5-12kbp in peripheral blood 
leukocytes [37] in humans and is highly variable among individuals. The observed range may 
be detectable as early as in the germline with reported variable telomere lengths of human 
semen samples ranging from less than 9 to over 17kb [38]. Furthermore, telomere length 
may at least partly be an inherited trait as described by Jesper et al. [39]. 
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 Figure 2:  T-Loop structure of the telomeric region (adapted from Griffith et al. [33]).  
 The blue and yellow ovals depict TRF1 and TRF2 (telomeric repeat–
binding factors 1 and 2, respectively), providing a protective mechanism 
for the telomeric ends. The red string shows the [TTAGGG]n sequence, in 
green [CCCTAA]n, and in black the non-telomeric DNA. 
 
2.5.2 Cellular Senescence 
Based on the theory of marginotomy by Olovnikov et al. in 1973 [29], telomeres have been 
described as the internal “mitotic clock” of cells. The erosion of telomeric sequences with 
each cell division may eventually lead to a critical telomere length, which in return leads to a 
p53-dependent growth arrest. This process was first described by Hayflick et al. [40], who 
observed that this growth arrest occurred after a specific number of cell divisions in human 
diploid cell strains, which was termed the “hayflick limit”. This phenomenon later became one 
of the cornerstones of the theory of replicative scenescence [41]. Groundwork for this theory 
has also been laid by Wright et al. which, based on the results of  in their experiments with 
SV40 (Simian vacuolating virus 40) transfected humand diploid fibroblasts, proposed a two-
stage model for cellular scenescence [42]. The first stage termed Mortality Stage I represents 
a p53-dependent arrest in phase G1/S of the cell cycle. Notably, Greider et al. found that the 
initial length of telomeric terminal restriction fragments is directly proportional to the 
replicative capacity of a cell line [43] and thus supporting the concept of replicative 
senescence in accordance with Choudhury et al., who showed  that the p53/23 induced cell 
cycle arrest is activated by telomere shortening and dysfunction [44]. The second stage 
(Mortality Stage II), in an attempt to undergo cell division, leads to a cellular crisis 
characterized by extensive telomere dysfunction and chromosomal instability leading to cell 
death [45].  
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 Figure 3:  Mortality Stage I and II in cellular senescence. The concept of cellular senescence 
illustrated by a gradual decrease of telomere length during cell replication (divisions).  
Two mechanisms, either by artificially inducing active telomerase (b) or by 
overcoming a p53-dependent cell cycle arrest (curved brown arrow), are shown to 
escape Mortality Stage I, possibly leading to the formation of tumor cells (c). (a) 
shows cells with active telomerase, which do not undergo telomere shortening. 
Figure adapted from Harley et al. [46] 
2.5.3 Telomerase 
Cells without limitations in their replicative capacity such as tumor cell lines or embryonic 
stem cells are obviously in need of a mechanism which can escape the status of cellular 
senescence. A specific telomere terminal transferase (termed telomerase) adds tandem 
[TTGGGG] repeats onto synthetic telomere primers in yeasts maintaining the telomeric 
region despite continuous cell divisions [47]. Further investigation showed that the active 
enzyme telomerase is a ribonucleoprotein containing two subunits, the catalytic subunit 
hTERT (human telomerase reverse transcriptase) and the template-containing RNA subunit 
hTR (human telomerase RNA). Telomerase or its catalytic subunit, respectively, is expressed 
in approximately 98% of immortal cell lines [48], germ cell lines and many types of tumors. 
However, telomerase is not an oncogene as telomerase activity does not necessarily lead to 
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loss of growth control, a process which needs to be clearly separated from cell 
immortalization as it is seen in human embryonic stem cells [49] or germline cells.  
2.6 Scaffold material 
For most applications, a suitable scaffold material for generating a graft that measures up to 
the demands and conditions of an in vivo tissue-specific environment is required. The 
prerequisites are extensive and should feature structural properties similar to natural 
extracellular matrix. For vascular tissue engineering, polymeric scaffold materials are mainly 
used due to their favorable properties. With the improvement of production techniques, such 
as electrospinning to create polymeric nanofibers [50,51], there is a trend to further 
functionalize scaffold materials based on nanotechnology as it is the case with the 
incorporation of drug-delivery vehicles in biodegradable polymeric scaffolds [52].  
Table 1: Basic characteristics of an ideal tissue scaffold, adapted from Murugan et al. [53] 
Characteristics General remarks 
Biologically compatible to host tissue (i.e., should not provoke any rejection, 
inflammation, and immune responses) 
Biocompatible 
The rate of degradation must perfectly match the rate of tissue regeneration, and the 
degraded product(s) should not harm the living tissues 
Biodegradable 
Vascular supportive Should provide channels for blood supply for fast and healthy tissue regeneration 
Nontoxic Should not evoke toxicity to tissues 
Nonimmunogenic Should not evoke immunogenic response to tissues 
Noncorrosive  Should not corrode at physiological pH and at body temperature 
To maximize the space for cellular adhesion, growth, extra-cellular matrix secretion, 
revascularization, adequate nutrition and oxygen supply without compromising 
mechanical strength 
Porosity with 
interconnected pores 
3D structure To assist cellular ingrowth and transport of nutrients and oxygen 
High surface area to 
volume ratio To accommodate high-density cells 
Surface modifiable To functionalize chemical or biomolecular groups to improve cell adhesion 
To withstand in vivo stimuli Adequate mechanical 
strength 
Sterilizable To avoid toxic contamination 
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2.7 Working hypothesis and study outline 
Caused by tissue remodeling and growth processes and the accelerated expansion phase in 
vitro to produce a sufficient amount of cells for of a tissue engineered vascular graft, we 
hypothesize that there is a significant difference in the biological age of the tissue-engineered 
vascular grafts compared to their native counterparts.   
To validate the reduction in telomere length during cell expansion, myofibroblasts were 
isolated from the external jugular and great saphenous vein of three Swiss White Alpine 
lambs. The cells were serially passaged and relative telomere length of cultured cells 
measured by Flow-FISH (fluorescent in-situ hybridization) analysis. The absence of 
telomerase activity of the isolated cell populations were confirmed by a telomere repeat 
amplification protocol (TRAP). 
To investigate the age of native and tissue engineered blood vessels, explant specimens of 
TEVG 5, 20, 50, 100 and 240 weeks post-implantation in an growing sheep model were 
evaluated using Q-FISH (quantitative fluorescent in-situ hybridization) analysis.  
Furthermore, immunohistological analysis of the tissue engineered implants at the site of 
anastomosis to further unravel the cellular remodeling mechanisms have been performed. 
  
 16  
3 Material and Methods 
3.1 Blood vessel tissue engineering and implantation 
Generation and implantation of tissue engineered pulmonary arteries in a growing sheep 
model was performed earlier by Hoerstrup and coworkers. Briefly, endothelial cells were 
obtained from segments of carotid artery and jugular vein derived from Swiss White Alpine 
lambs (age: 44±2 days, weight: 15.58±5.55 kg, n=6) using collagenase digestion [6]. 
Myofibroblasts were extracted from the remaining de-endothelialized vessel segments and 
used after about 16 doubling times (average doubling time: 28.3 h ± 6.6 h, n=6). The 
expanded myofibroblasts were seeded in three fractions onto PGA/P4HB composite arterial 
scaffolds (18 mm ± 1 mm) in 24h intervals (4.5E6 to 5.5E6 cells per cm2) under static culture 
conditions using Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA) 
supplemented with 10% lamb serum (GibcoBRL; Cat. No. 16070096, Lot. No. 6050576D). 
Thereafter, the conduits were covered with endothelial cells (1E6 per cm2). After additional 
three days grown under static culture conditions, the vascular grafts were placed into a pulse 
duplicator bioreactor system [6], and grown under gradually increasing flow conditions (50 
mL/min to 550 mL/min, 1Hz) for 14 days. The culture medium was changed every three to 
four days. The tissue engineered vascular grafts were implanted into lambs (n = 6, 165±46 
days old, 27.33±3.84 kg). The heart was exposed by a left anterolateral thoracotomy through 
the third intercostal space. Cardio-pulmonary bypass was performed via right femoral artery 
and right atrial cannulation. Following exposure and mobilisation of the main pulmonary 
artery, approximately 2cm of native pulmonary artery was excised. Experimental duration 
was up to 240 weeks, representing the full biological growth cycle of this animal model. 
Animals included in this study were analyzed after 5, 20, 50, 100 and 240 weeks post 
mortem.  
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3.2 Ovine cell isolation and culture 
Segments of 3-4cm in length of the external jugular vein (OVJ) and the great saphenous vein 
(OVS) of three Swiss White alpine lambs aged 4-6 months were harvested and transferred to 
the lab on ice immediately. The pieces were washed in PBS (Kantonsapotheke, Zurich, 
Switzerland), manually stripped of the surrounding adventitial tissue and minced into small 
pieces of approximately 2-3mm. Collagenase digestion was conducted using DMEM medium 
(Gibco, Invitrogen, CA, USA) supplemented with 2ug/ml of Collagenase A (Roche 
Diagnostics GmbH, Switzerland) and 5% 1M Hepes buffer (Gibco). The solution was 
incubated for 2h in a humidified atmosphere at 37°C containing 5% CO2. A magnetic stirrer 
was used to ameliorate separation of the cells mechanically. The cell suspension was then 
strained (Falcon 20µm cell strainer) and transferred to a cell culture flask. The isolated cells 
were expanded as monolayer cultures in DMEM supplemented with 10% Lamb Serum 
(Gibco), 2mM Glutamax (Gibco) and 1% Penicillin/Streptpmycin (Gibco). Medium was 
exchanged every 3 days and cell cultures split at subconfluency at a ratio of approximately 
1:4. Cells were cryopreserved in liquid nitrogen at -196°C using Lamb Serum (Gibco) and 
10% DMSO Hybri-Max (Sigma) until further use.  
3.3 Flow-FISH (fluorescent in-situ hybridization) 
Relative telomere length was measured according to the manufacturer’s protocol for Flow-
FISH analysis (Telomere PNA Kit/FITC, Dako, Glostrup, Denmark). Briefly, DNA of 
cryopreserved ovine external jugular and great saphenous vein myofibroblasts was 
denaturized for 15min at 82°C and hybridized using a ready-to-use hybridization solution 
(DakoCytomaton) containing 70% formamide for non-stained cell samples and a FITC-
conjugated PNA telomere probe targeted to the repetitive telomere sequence [TTAGGG]n, 
respectively. The hybridization (overnight in the dark at room temperature) was followed by 
washing twice with a wash solution for 10min at 40°C. After washing, the samples were 
resuspended in DNA-staining solution containing propidium iodide (PI) and RNase A. After 
incubation of a minimum of 2 hours at 4°C, samples were measured using a fluorescent cell 
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sorter (FACS Calibur, BD Biosciences, Belgium) and analyzed with FlowJo software Version 
7.5 (Tree Star Inc, Ashland, Oregon, USA). PI was used to gate only for the cells which are 
in G0/G1 cell cycle state. As control cell line, we used the tetraploid human T cell line 1301, a 
sub-line of the EBV genome negative T-cell leukaemia line [54] obtained from Interlab Cell 
Line Collection (IST), Genova, Italy. The ratio between the mean fluorescence intensity (MFI) 
of the myofibroblasts and the control cell line is expressed as the relative telomere length 
ated as:  (RTL), calcul
RTL ൌ 100 x 
ሺMFI MF with PNAିMFI MF without PNAሻൈଶ DNA Index 1301 
MFI 1301 with PNA –MFI 1301 Without PNA
  whereas PNA signal is represented in the  
FL-1 channel and PI in the FL-3 channel.  
3.4 Telomerase Activity (TRAP and ELISA)  
Telomerase activity was measured using the TRAP telomeric repeat amplification protocol 
according to the kit’s manufacturer (TeloTAGGG Telomerase PCR ELISA, Roche 
Diagnostics GmbH, Switzerland). Cell pellets consisting of 2x10E5 cells were stored at -80°C 
until performing the assay. The samples were resuspended in lysis reagent (Roche 
Diagnostics) and incubated on ice for 30min before the lysate was centrifuged at 4°C and 
16000xG for 20min before performing the TRAP reaction. To create negative controls, cell 
extracts were heat-treated for 10min at 85°C prior to the TRAP reaction. 3µl of the cell 
extracts, the positive controls supplied by the manufacturer and the reaction mixture (Roche 
Diagnostics) containing telomerase substrate, primers, nucleotides and Taq polymerase 
were transferred to Eppendorf tubes suitable for PCR amplification. The amplification was 
carried out using an Eppendorf Mastercycler (Eppendorf, Netheler, Germany). The 
elongation of a biotin-labeled synthetic primer by the telomerase enzyme leads to non-
uniform “elongation products” (telomerase specific 6-nucleotide increments). These are then 
amplified by Taq DNA Polymerase. The amplification product was denatured and incubated 
for 10min at room temperature (denaturation reagent, Roche Diagnostics), then hybridized 
over 2h at 37°C (hybridization buffer, Roche Diagnostics) to digoxigenin-labeled detection 
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probes. The hybridization mixtures were transferred to streptavidin-coated microplate 
modules and incubated for another hour at 37°C. The wells were washed (washing solution, 
Roche Diagnostics) three times before Anti-DIG-POD working solution (containing anti-
digoxigenin-peroxidase, Roche Diagnostics) was added. The plate was covered with foil and 
incubated for 30min at room temperature while shaking at 300rpm. The samples were rinsed 
5 times (washing solution, Roche diagnostics) and TMB substrate solution (Roche 
diagnostics) containing the POD substrate 3,3´,5,5´-tetramethyl benzidine was added. After 
20min of color development at room temperature, the stop reagent (Roche diagnostics) was 
added and the absorbance at 450nm was measured against blank of 750nm using a 
microplate reader within 20min after addition of the stop reagent. Results are reported as 
absorbance values: ∆A ൌ A450 െ A750. Samples are considered positive if the difference in 
absorbance ∆ܣ is higher than 0.2 
3.5 In-situ Q-FISH  (quantitative fluorescent in-situ hybridization) 
Paraffin sections of cryopreserved tissue-engineered explanted grafts, the anastomosis site 
and its adjacent vascular tissue, respectively, were dewaxed and rehydrated in descending 
ethanol series and rinsed with PBS. After incubation in sub-boiling citrate buffer for a 
cumulative 30 minutes, the slides were incubated for 10min in pepsine solution (1mg/ml ,pH 
2.0) at 37°C. After dehydration in ascending ethanol series, the slides were air dried before 
adding 15µl of the hybridization mix containing 70% formamide, 0.5µg/ml PNA probe 
(5µl/250µl, 25µg/ml PNA), 0.5% Blocking reagent (12.5µl/250µl,10% Solution, Roche), 
8.56% Magnesiumchloride buffer (25mM Magnesiumchloride, 9mM Citric acid, 82mM 
Disodiumhydrogenphosphate) and 10% 1M Tris pH 7.2. DNA was denatured by heat 
treatment for 3min at 80°C. After hybridization for 2h in a humid chamber, slides were 
washed with 70% Formamid/10mM Tris pH 7.2/0.1% BSA followed by TBS-Tween 1% and 
PBS. Slides were dehydrated using ascending ethanol series and air dried. Antifade and 
DAPI (Vectashield, Vector #H1200) mounting solution and a coverslip were applied. Digital 
images were recorded with a Leica microscope equipped with a monochromatic digital 
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camera (Leica Microsystems, Wetzlar, Germany). Image analysis was performed with TFL-
Telo Version 2.2 for Windows software as describe by Poon and Landsorp [55]. 
Fluorescence intensities of PNA labeled telomeres were measured in the central part of the 
tissue engineered construct and compared to sections which included native vascular tissue 
adjacent to the anastomosis site on the same histological section. 
3.6 Statistical Analysis 
Statistical analysis including histograms and boxplots was carried out with PASW Statistics 
Version 18 for Windows (SPSS Inc., Chicago, IL, USA). Q-FISH data underwent a Mann-
Whitney-U-Test to test for statistical significance. The null-hypothesis was rejected for p-
values greater than 0.05.  
3.7 Immunohistological Analysis 
Immunohistochemistry was performed using the Ventana Benchmark automated staining 
system (Ventana Medical Systems, Tuczon, Arizona) and the following primary antibodies: 
Anti-vimentin (clone 3B4, DakoCytomation, Glostrup, Denmark), anti-desmin (clone D33, 
DakoCytomation, Glostrup, Denmark) and anti-α-smooth muscle actin (α-SMA, clone 1A4, 
Sigma Chemical Company, St. Louis, MO, USA), anti-vascular endothelial growth factor 
(VEGF) (AK77, Lab Visison, Fremont, CA, USA) and anti-Ki67 (Mib-1, DakoCytometry). 
Primary antibodies were detected with the Ventana iVIEW DAB detection kit, resulting in a 
brown reaction product. Slides were counterstained with haematoxylin and covered with a 
glass cover slip. 
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4 Results 
4.1 Telomerase Activity (TRAP and ELISA) 
Measurement of telomerase activity in three different ovine myofibroblast cell cultures (OVS 
and OVJ respectively) passaged three to four times (P3 and P4) yielded negative results with 
a mean absorbance values of five different measurements at 450nm of 0.063 A450-A750 for 
OVS 1 P3, 0.076 A450-A750 for OVJ 2 P3 and 0.051 A450-A750 OVJ 3 P4 against the reference 
wavelength of 750nm. Samples are considered negative if the difference of negative controls 
(not shown in the graph) to the corresponding samples is less than 0.2 A450-A750 units. The 
assay was validated with positive controls supplied by the manufacturer within the specified 
range (higher than 1.5 A450-A750). We also measured telomerase activity in 1301 cell line, 
which was later used to determine relative telomere length. It showed active telomerase as 
expected.  
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Figure 4:  Telomerase activity of ovine myofibroblasts (OVS 1 P3, OVJ2 P3 and 
OVJ 3 P4). The absence of telomerase activity in all measured ovine 
myofibroblasts is confirmed by positive results for the positive contol 
(supplied by the manufacturer) and the telomerase-active 1301 cell 
line. The error bars indicate +1 Standard Deviation over all 
measurements. 
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4.2 Flow- FISH / Telomere length 
Relative Telomere length (RTL) of three Swiss Alpine lambs were measured after 2-4, 13-16, 
26-32 and 44-54 population doublings. Cells of all lambs were measured in two separate 
experiments as shown in Figure 5 to ensure internal consistency of the obtained results. 
Serial passaging of myofibroblasts with a mean population doubling time of approximately 
31-38 hours for all ovine myofibroblasts resulted in a decrease of relative telomere length of 
25.8%-32.3% over 41-44 population doublings with an approximate linear reduction of 
relative telomere length as indicated by the coefficients of determination tending towards 1.0 
(R2OVS 1A=0.9981, R2OVS 2A=0.9365 and R2OVJ 3A=0.988) for linear regression. One sheep (OVS 
1) showed significantly longer RTL than the other two, pointing towards interindividual 
differences of absolute telomere length [56]. However, Flow-FISH was not sensitive enough 
to reliably separate mixed cell populations with different population doublings.  
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Figure 5:  Overview of all measured relative telomere lengths. RTL of the 
saphenous vein (OVS 1) were significantly higher than in the other 
two lambs (OVJ 2 and 3). This may be due to interindivdual 
differences or the different isolation location (saphenous vs. external 
jugular vein in OVJ 2 and 3)  
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 Figure 6: Decrease of Relative Telomere Lengths of isolated ovine myofibroblasts. 
  All measured cell lines showed an approximate linear decrease of telomere 
lengths. Each cell line was measured in two individually processed samples 
(Samples A and B). 
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 4.3 Telomere Fluorescence in TEVG vs. Native  
After follow-up periods of 5, 20, 50, 100 and 240 weeks, tissue-engineered pulmonary artery 
conduits and native vessel wall neighboring the anastomosis site from 5 Swiss Alpine Lambs 
were explanted, fixed and embedded in paraffin wax until further use. Sections were made 
from each of the three regions of interest, the central part of the conduit (TEVG), the 
anastomosis site and native vessel (Native), respectively. 1-3 sections of the central part of 
the conduit and the native vessel were processed and images captured of 10 different 
regions on the slides. Slides were processed for Telomere Q-FISH analysis. For each slide 
region the median fluorescence value was computed, accounting for data outliers caused by 
bad image quality or staining errors.  
4.3.1 5 Weeks TEVG vs. Native 
5 weeks post implantation specimens of TEVG and Native showed equally distributed 
fluorescence intensities across all measured datasets. 29 datasets for Native and 30 
datasets for TEVG recorded from three different slides 
show a lower mean and median value for TEVG 
compared to Native. A conducted Mann-Whitney-U-
Test attested statistical significance for the obtained 
distribution with a p-value <0.01. As a consequence, 
telomere lengths of the TEVG are significantly shorter 
than those of its native counterpart.  
were available for analysis. Results 
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 Figure 7:  Histogramm of measured fluorescence intensities 5 weeks post 
implantation. The boxplot shows minimum, first quartile, median, third 
quartile, and maximum. Extreme values are not shown in the plot. The 
Mann-Whitney-U-Test shows statistical significance for distribution with  
p<0.01. 
 
4.3.2 20 Weeks TEVG vs. Native 
20 weeks post implantation, 2 sets of slides of two different sheep were available for 
analysis. The first Set (Set 1) contained 29 datasets for Native and 30 datasets for TEVG 
recorded from three slides each. The second Set (Set 2) contained 18 datasets for Native 
and 20 datasets for TEVG recorded from 3 and 2 slides, respectively. S1 distribution 
descriptively shows a different mean (1676.61 vs. 2102.17) value with only slightly differing 
medians (1090.06 vs. 1133.24). In contrast to S2, a Mann-Whitney-U-Test on S1 failed to 
ce in distribution (p=0.155).  show a statistically significant differen
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 Figure 8:  Histogramm of measured fluorescence Intensities 20 weeks post 
implantation (Set 1). The boxplot shows minimum, first quartile, median, 
third quartile, and maximum. The Mann-Whitney-U-Test shows no 
statistically significant difference in distribution.   
 
Figure 9:  Histogramm of measured fluorescence Intensities 20 weeks post 
implantation (Set 2). The boxplot shows minimum, first quartile, median, 
third quartile, and maximum. The Mann-Whitney-U-Test shows statistical 
significance in distribution with  p<0.01. 
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4.3.3 50 Weeks TEVG vs. Native 
50 weeks post implantation, 7 datasets for Native and 18 datasets for TEVG were available 
for analysis. Results show a statistically significant lower median value for TEVG (1065.71) 
vs. Native (1601.38) with  p<0.01.   
 
 
 
 
 
 
 
 
Figure 10:  Histogram and Boxplot 50 weeks post implanation. For Native n=936 
datapoints were included. The Mann-Whitney-U-Test shows statistical 
significance in distribution with p<0.01. 
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4.3.4 100 Weeks TEVG vs. Native 
100 weeks post implantation, 2 sets of slides from two different sheep were available for 
analysis. The first Set (S1) contained 25 datasets for Native and TEVG each. The second 
Set (S2) contained 28 datasets for Native and 29 datasets for TEVG. For both Sets, the 
median values of the TEVG (1068.02 and 856.87) were significantly lower than those of 
0.01 for both sets.  
 
Native (1601.38 and 1114.05) with p<
 
Figure 11:  Histogramm of measured fluorescence Intensities 100 weeks post 
implantation (Set 1). The boxplot shows minimum, first quartile, 
 
 
 
 
 
 
 
median, third quartile, and maximum. The Mann-Whitney-U-Test shows 
statistical significance in distribution with a p<0.01. 
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Figure 12:  Histogramm of measured fluorescence Intensities 100 weeks post 
implantation (Set 2). The boxplot shows minimum, first quartile, 
median, third quartile, and maximum. The Mann-Whitney-U-Test shows 
statistical significance in distribution with a p<0.01. 
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4.3.5 240 Weeks TEVG vs. Native 
240 weeks post implantation specimens of TEVG and Native showed unevenly distributed 
fluorescence intensities across the measured datasets. 25 datasets for Native and 17 
datasets for TEVG were available for analysis. After correcting for data outliers, a statistical 
significance between Native and TEVG telomere length could not be detected. However, 
compared to the other measured datasets, this set contained large differences in the means 
of each slide, especially in the TEVG, where median flu
arbitrary units to 1230.22 units in the acquired datasets. 
Details are shown in Figure 14.  This implies that some 
cells have very short telomeres, whereas a 
considerable amount of cells has telomere lengths 
comparable to the native vessel (range 453.16 to 
1016.9 arbitrary units). 
orescence values range from 327 
 
Figure 13:  Histogramm of measured fluorescence Intensities 240 weeks post 
implantation. The boxplot shows minimum, first quartile, median, third quartile, 
and maximum. A statistically significant difference in distribution could not be 
detected.  
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4.3.6 Overview of mean and median fluorescence intensities of acquired datasets 
 
 
Figure 14:   Measured median fluorescence values of the telomeric probes and calculated 
median of all explanted TEVG and Native tissue. The black bars represent the 
median values of measured fluorescent intensites of the individual slides. The 
red bars represent the mean of all measured medians. The error bars represent 
1 standard deviation over all measurements.  
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4.4 Histological Analysis of Tissue Remodeling 
Histological analyses from sections of tissue engineered pulmonary arteries obtained after 20 
and 100 weeks post implantation and native tissue histologically show similarly configured 
TEVGs (A and F) compared to Native (K) with an endothelial layer to the luminal side with 
scattered smooth muscle cells and proprietary capillary vessels embedded in a fibrous tissue 
in the tunica media and its adjacent adventitia. Staining for the proliferation marker Ki67 [57] 
shows increased proliferative activity within the TEVGs (B and G) in the media. Likewise, 
VEGF could be identified in the TEVGs (C and H), but mainly co-localized around residual 
fibers within polynucleated giant cells, therefore arguing against a state of ubiquitous hypoxia 
in TEVG. At the anastomosis site, a growth cone positive for Desmin, an intermediate 
filament in the cytoskeleton of smooth muscle cells [58], is visible after 20 and 100 weeks (D 
and I), suggesting a continuous merging and replacement of cells with a smooth muscle 
phenotype into the tissue-engineered graft. The latter are characterized by positive staining 
for Desmin and alpha-SMA [59]. (N) illustrates the localization of the histological specimens 
from the center of the graft as well as from the anastomosis. 
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Figure 15: Overview of immunohistological analyses 20 and 100 weeks post implantation.  
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5 Discussion 
5.1 Telomere Flow-FISH and Q-FISH analysis 
Flow-FISH provides an interesting tool to evaluate large cell numbers and is especially useful 
when cells are in a suspended state, typically during the fabrication process of TEVG. We 
used a commercially available kit to assess telomere lengths during the expansion of ovine 
myofibroblasts. The results show an approximately linear reduction of relative telomere 
length during serial passaging.  As a consequence, telomere lengths differ only slightly in the 
lower range between 2 and 16 population doublings, which is normally the desired range for 
tissue engineering purposes. Telomerase was shown to be absent in all measured cell 
populations and therefore has no implication in this experimental setting. Yet, mixed cell 
populations with large differences in population doublings could not be distinguished by 
Flow-FISH because of the wide range of the measured fluorescence values corresponding to 
telomere length (see appendix for details). This poses the main drawback to distinguish 
native cells and cells originating from tissue engineered constructs using telomere length 
determination by Flow-FISH.  
In-situ based Q-FISH determines telomere length on a single cell basis staining for telomeric 
sequences with peptide nucleic acid (PNA) of all exposed chromosomes. Quantification can 
be obtained by using internal controls and fluorescent beads to correct for differences in 
staining intensities, exposure times and fluorescence lamp intensity variations [60]. Our 
results clearly indicate that telomeres are shorter in almost all measured samples of TEVG 
compared to the native vessel. How this is thought to be related to cellular aging, graft 
fabrication and remodeling processes is discussed in the following sections. Different median 
fluorescent intensities of all measured Native samples between different sheep may be due 
to differences in sample quality and processing or due to inter-individual differences of the 
lambs. As described above, quantitative analysis would require the additional use of 
fluorescent beads and internal controls with cells with already known telomere length, which 
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are commercially available. This should be included in future studies. Furthermore, telomere 
length measurements using in-situ based Q-FISH before and after the bioreactor phase 
would allow for quantification of telomere length reduction during the individual fabrication 
processes and could even be quantified in relation to post-implantation processes.   
5.2 Remodeling processes 
Understanding the cellular remodeling processes after graft implantation is crucial to facilitate 
the design of tissue replacements in regard to functionalized scaffold materials [61] and 
suitable cell sources [6, 62]. According to the presented results, there is strong evidence by 
histological, phenotypical and cell ageing analyses that in a growing organism, the 
myofibroblasts used to produce the TEVG are being at least partially replaced by native cells 
surrounding the TEVG. Several mechanisms are feasible by which the cells are replaced: (i) 
classical inflammation and connective tissue repair by the recipient which then remodels to 
functional tissue with near-appropriate cell phenotypes and extracellular matrix [63]; (ii) 
homing of blood-bound stem or progenitor cells that settle within the graft; (iii) myofibroblasts 
invade the TEVG from the adventitia surrounding the graft; (iv) the TE graft is 
invaded/encapsulated from the sides of the anastomosis and (v) a combinatorial mechanism 
from the above mentioned. The proposed mechanisms are illustrated in Figure 16.  
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 Figure 16: Remodelling processes over 100 weeks of a tissue engineered vascular 
graft. [A:] Ingrowth from the sides of anastomosis and the adjacent 
adventitia [B]. [C] represents in-graft remodeling via inflammation and 
growth processes. [D]: Recruitment of circulating stem or progenitor cells. 
Time indicators show the progression of remodeling processes towards a 
fully functional graft resembling native vascular tissue over a completed 
growth cycle of the animal model. 
5.3 Scaffold material 
Based on the proposed remodeling processes, our observations indicate that grafts for 
cardiovascular tissue engineering need to serve as synthetic or living biological matrix that 
guides and/or induces healing processes in vivo, which clearly is mediated by endogenous 
cells.  
In vascular tissue engineering, the scaffold typically is a resorbable polymer with key 
biological information that drives effective functional remodeling of the substrate. Off-the-
shelve grafts would be superior to “functionalize” fast degrading polymers with autologous 
cells in biomimetic reactors. Yet, this is a complex and time consuming process. The 
demands on such biomaterials are very high: (i) adequate mechanical strength but still 
elastic to propagate the sinus wave, (ii) immunological inert, (iii) no tendency to stenosis or 
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stricture formation, (iv) enable controlled cellular ingrowth, (v) well balanced scaffold 
degradation - tissue formation kinetic and (vi) not subject to immediate or fast calcification.  
To match the complexity of mechanical, cellular and molecular biological cues provided by 
living engineered tissues, will be a highly challenging attempt to be recreated by biomaterial 
scientists. First steps towards functionalized tissues have been taken. Carbon nanotubes 
may aid in the process of tissue development not only as a structural reinforcement of 
today’s typically used scaffolds in the fabrication process [64,65] but also as a part of a 
functionalized scaffold material with directed cell growth for example by using the electrical 
conductivity of carbon nanotubes [22,66]. Furthermore, they can potentially be used to 
release bioactive factors to provide a scaffold material tailored to demand.  
5.4 Aging of TEVG 
The obtained results show that telomere length in tissue-engineered grafts is, for the most 
part, significantly lower than in the native arteries. There are several mechanisms possible as 
how telomere length can be decreased: (i) An increased cell turnover during the remodeling 
process due to increased shear stress and inflammation processes. This was also proposed 
by Okuda et al. [67], who detected shorter telomeres in parts of the aortic wall with a higher 
shear stress, a factor, which could also play a role in this animal model before, during the 
bioreactor phase, or after implantation. Matthews et al. [68] detected a decrease in telomere 
length with a quantitative telomere/immunostaining fluorescence in-situ hybridization (TELI-
FISH) in atherosclerotic plaques in human vascular smooth muscle cells (VSMC) compared 
to cells in the tunica media of the same lesion. This was thought to be due to additional 
replications involved in lesion development but he also identified (ii) oxidative stress to have 
a substantial influence on telomere length in vitro. Similar results came from Kurz et al. [69]. 
Even though we could not detect an ubiquitous appearance of VEGF in the graft by 
immunohistochemistry, a higher oxidative stress in the grafts due to insufficient proprietary 
small vessels during the first phase after implantation cannot be ruled out. Based on the 
demonstrated remodeling processes, we have to conclude that telomeres are reduced at 
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least partly due to cell division or replacement. Even though our data show, that telomeres 
are reduced during the initial fabrication process, some grafts show no significant difference 
in telomere length, suggesting that the observed decreased telomere length in the TEVG is 
not solely explained by cell expansion during the fabrication process. Also, the time 
necessary to reach a sufficient number of cells typically does not exceed a 14 day period, 
which corresponds to approximately 10 populations doublings (calculated by a mean 
population doubling speed of 35 hours) in this animal model. Our data suggest that telomere 
length is not substantially decreased during this time period. Unfortunately, the lack of pre-
implant telomere analysis does not allow us to quantify which process (expansion and 
bioreactor phase or post-implantation processes) affects telomere lengths the most.   
5.5 Clinical implications 
Tissue engineering, and in this particular case TEVG positioned in a pulmonary artery, aims 
at eventually providing an alternative approach to the reparation of congenital cardiac 
lesions. Current conduits for reconstruction of the right ventricular outflow tract (RVOT) 
consist of valved aortic or pulmonary homografts or stented bovine or porcine xenografts and 
other prosthetic conduits [70], whereas the pulmonary homograft is considered the gold 
standard. Major drawbacks, in many cases, include the need of graft replacement due to 
conduit failure during growth and development of the patients. A failure rate of approximately 
40% at 10 years has been reported [71]. Conduit failure is not limited to somatic outgrowth 
and includes conduit contracture or shrinkage, conduit kinking, sternal compression, 
posterior muscle shelf impingement and distal anastomotic stenosis [71]. Also, immunologic 
reactions to the implanted homografts are held responsible for conduit failure as proposed by 
Neves et al. [72] and Hawkins et al. [73] amongst others. 
Thus far, autologous cell-based tissue-engineered vascular grafts have been shown to be 
largely free of side effects such as dilatation, stenosis, acute and chronic inflammatory 
responses or thrombus formation [6]. We have shown that production and remodeling 
processes of TEVG lead to a premature aging, expressed in shorter telomere lengths. 
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Further analyses by Hoerstrup and coworkes show that the implanted TEVG are fully 
functional over a complete lifecycle of the chosen animal model. This implies that telomeres 
overall do not shorten to a critical length, which may lead to cellular senescence. As we have 
seen from the results 240 weeks post implantation, telomere lengths of the TEVG were 
highly variable. This could be due to ongoing remodeling or inflammation processes coupled 
with extensive cellular replacement, and thus restoring mean telomere length and replacing 
dysfunctional and maybe senescent cells. From a clinical point of view and accounting for the 
results obtained in this study, conduit replacements during a patient’s lifetime may not be 
completely avoided. Yet, it is possible that necessary re-operations may be deferred to a 
more convenient point of time. Most importantly, results have showed that the implanted 
grafts survive in a fully functional state and grow over the host animal’s life cycle.  
However, the dogma of tissue engineers to create fully functional biological substitutes to 
enable adequate immediate and long-term in vivo functionality has to be questioned. 
Implantation of TE grafts which are developed to a point at which they have developed 
enough extracellular matrix to cope with the mechanical demands might be sufficient for 
long-term in vivo functionality. To further unravel the complex mechanisms of cellular 
remodeling and replacement processes of tissue engineered grafts, future efforts of 
biomaterial scientists and tissue engineers will be mandatory to optimize the design 
parameters of cardiovascular grafts and their successful clinical use in the future. 
Telomeres are currently highly focused on in the field of aging and development, as well as 
experimental oncology to develop new methods for tumor suppression. Tissue engineering is 
represented in all these domains, trying to offer new treatment strategies and concepts.  With 
further advances in the field of tissue engineering in regard to the development of 
biomaterials and cell sources, the demand for monitoring methods is continuously rising. We 
conclude that through this study, we have successfully added telomere length analysis to this 
toolbox. 
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8.2 FACS dotplots Samples B (OVS1, OVJ2, OVJ3) 
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8.3 Telomeric fluorescence:  Native and TEVG 
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